| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CYP2C19 |
| Uniprot No | P33261 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 26-490aa |
| 氨基酸序列 | RGKLPPGPTPLPVIGNILQIDIKDVSKSLTNLSKIYGPVFTLYFGLERMVVLHGYEVVKEALIDLGEEFSGRGHFPLAERANRGFGIVFSNGKRWKEIRRFSLMTLRNFGMGKRSIEDRVQEEARCLVEELRKTKASPCDPTFILGCAPCNVICSIIFQKRFDYKDQQFLNLMEKLNENIRIVSTPWIQICNNFPTIIDYFPGTHNKLLKNLAFMESDILEKVKEHQESMDINNPRDFIDCFLIKMEKEKQNQQSEFTIENLVITAADLLGAGTETTSTTLRYALLLLLKHPEVTAKVQEEIERVVGRNRSPCMQDRGHMPYTDAVVHEVQRYIDLIPTSLPHAVTCDVKFRNYLIPKGTTILTSLTSVLHDNKEFPNPEMFDPRHFLDEGGNFKKSNYFMPFSAGKRICVGEGLARMELFLFLTFILQNFNLKSLIDPKDLDTTPVVNGFASVPPFYQLCFIPV |
| 预测分子量 | 60.6 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3-4条关于CYP2C19重组蛋白的参考文献及简要摘要概括：
---
1. **文献名称**: "Expression and Functional Characterization of Cytochrome P450 2C19 in *Escherichia coli*"
**作者**: Dickinson, R. G., et al.
**摘要**: 研究通过在大肠杆菌中重组表达CYP2C19蛋白，优化表达条件并验证其酶活性(如奥美拉唑羟化酶活性)，证明重组蛋白可用于体外药物代谢研究。
2. **文献名称**: "Pharmacogenetics of Cytochrome P450 2C19: Genetic Variants and Functional Consequences"
**作者**: Goldstein, J. A., et al.
**摘要**: 分析了CYP2C19基因多态性对酶功能的影响，利用重组蛋白系统验证不同突变体(如*CYP2C19*2、*3)的代谢活性差异，揭示其与个体化用药的关联。
3. **文献名称**: "Co-expression of Cytochrome P450 2C19 and NADPH-Cytochrome P450 Reductase in Baculovirus-Insect Cells"
**作者**: Rowland, P., et al.
**摘要**: 在昆虫细胞中重组共表达CYP2C19与还原酶，实现高效蛋白折叠及活性酶复合体生成，用于药物代谢动力学的高通量筛选。
4. **文献名称**: "Structural Insights into CYP2C19-Mediated Drug Metabolism through Crystallography"
**作者**: Annalora, A. J., et al.
**摘要**: 通过重组CYP2C19蛋白的晶体结构解析，阐明其底物结合口袋的构象变化，为设计针对该酶的药物提供结构基础。
---
**注**：以上文献信息为示例性概括，具体内容需参考实际发表的论文。建议通过PubMed或Web of Science检索关键词“CYP2C19 recombinant protein”获取最新研究。
CYP2C19 is a member of the cytochrome P450 (CYP) enzyme family, primarily expressed in the liver and involved in the metabolism of numerous clinically important drugs, including antiplatelet agents (e.g., clopidogrel), antidepressants, antifungals, and proton pump inhibitors. It plays a critical role in Phase I drug metabolism, facilitating the oxidation or reduction of substrates to enhance their elimination. Genetic polymorphisms in the CYP2C19 gene significantly influence enzyme activity, leading to interindividual variability in drug efficacy and toxicity. These polymorphisms categorize individuals into poor, intermediate, normal, rapid, or ultrarapid metabolizer phenotypes, driving personalized medicine approaches.
Recombinant CYP2C19 protein is engineered through heterologous expression systems (e.g., bacteria, yeast, or mammalian cells) to produce functional enzymes for research and drug development. This technology enables controlled studies of CYP2C19’s catalytic mechanisms, substrate specificity, and interactions with inhibitors or inducers. Recombinant proteins are pivotal in high-throughput screening for drug candidates, assessing metabolic stability, and predicting drug-drug interactions. They also aid in characterizing genetic variants’ functional impact, supporting pharmacogenomic research.
Applications extend to biosynthetic studies and structural biology, where recombinant CYP2C19 facilitates crystallography and molecular modeling to elucidate enzyme-substrate binding dynamics. Its use in vitro systems (often combined with cytochrome P450 reductase and NADPH) mimics hepatic metabolism, reducing reliance on human/animal trials. Challenges include maintaining enzyme stability and replicating native membrane environments. Nonetheless, recombinant CYP2C19 remains indispensable for advancing precision medicine and optimizing therapeutic outcomes.
×
